HomeAboutMediaCareersSite MapContactSearch
Geron
PatientsProductsTechnology & ScienceInvestors
print
Recent Publications
  • Nature Reviews Cancer
    8:167-179, March 2008
  • Nature Biotechnology
    25:1015-1024, Sept. 2007

News
  • 6/30/2009
    GE Healthcare and Geron Announce Exclusive Global Agreement to Commercialize Stem Cell Drug Discovery Technologies...more 
  • 6/10/2009
    Geron to Present at the 8th Annual Needham Life Sciences Conference...more 
Events
  • June 11, 2009
    9:30 am ET

    8th Annual Needham Life Sciences Conference,
    New York, NY
  • May 29, 2009
    8:30 am PT

    2009 Annual Stockholders Meeting
    Menlo Park, CA



Uncommon Medicine / Unlimited Potential

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell (hESC)-based therapeutics. The company has received FDA clearance to begin the world's first human clinical trial of a hESC-based therapy: GRNOPC1 for acute spinal cord injury.

Visionary Therapeutics
Home | About | Media | Careers | Site Map | Contact | Search
Patients | Products | Technology & Science | Investors
Legal Disclaimer
Copyright © Geron 2009. All rights reserved.